Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors.

The cyclin-dependent kinase inhibitor p27(Kip1) (p27) plays a pivotal role in controlling cell proliferation during development and tumorigenesis. p27 has been implicated in pituitary tumorigenesis in studies of knockout mice and in analyses of human pituitary tumor samples. In this study, we further explored the role of p27 in human pituitary tumors by measuring levels of phosphorylated p27 (P-p27), and also Jun activation domain-binding protein 1 (Jab1), which is thought to facilitate the phosphorylation and degradation of p27, in normal pituitary tissue (n = 21), pituitary adenomas (n = 75), and pituitary carcinomas (n = 10). The amount of p27 protein in corticotroph adenomas and pituitary carcinomas was much lower than that in normal pituitary tissue or other types of pituitary adenoma. Nuclear P-p27 protein levels were significantly decreased in the adenomas, compared with the normals, and were much lower in the carcinomas, compared with either normal pituitary tissue or pituitary adenomas. However, P-p27 levels in corticotroph adenomas were similar to normal pituitary tissue, thus demonstrating a greatly increased ratio of P-p27 to p27 specifically in corticotroph tumors. No difference was found in Jab1 protein levels in either corticotroph tumors or other pituitary adenomas, compared with normal tissue, but there was a small but significant increase in Jab1 levels in carcinomas. Corticotroph and metastatic tumors both showed a significantly higher Ki-67 labeling index than normal pituitary or other types of pituitary adenomas, and in general the Ki-67 labeling index was negatively correlated with p27 nuclear staining. The amount of p27 and Jab1 mRNA was positively correlated in all pituitary samples studied but did not correlate with the changes in immunostaining. Our findings suggest that in corticotroph tumors there is an accentuated phosphorylation of p27 into P-p27, possibly related to increased cyclin E expression, whereas both p27 and P-p27 are subject to increased degradation in pituitary carcinomas. Such variations in phosphorylation may play a role in pituitary tumorigenesis, but modulation of Jab1 is unlikely to be important in the pathogenesis of pituitary adenomas.

[1]  James M. Roberts,et al.  A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase , 2001, Nature.

[2]  S. Mccann,et al.  Release of leptin and its effect on hormone release from human pituitary adenomas* , 2001, Clinical endocrinology.

[3]  M. Korbonits,et al.  Expression of 11β-Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors , 2001 .

[4]  Y. Tsunematsu,et al.  Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma. , 2000, International journal of oncology.

[5]  B. Scheithauer,et al.  Glucocorticoid receptor expression in nontumorous human pituitaries and pituitary adenomas , 2000 .

[6]  P. Jackson,et al.  Nuclear accumulation of cyclin E/Cdk2 triggers a concentration-dependent switch for the destruction of p27Xic1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Korbonits,et al.  Cyclin D and cyclin E expression in normal and adenomatous pituitary. , 2000, European journal of endocrinology.

[8]  M. Ewen,et al.  Bcl-2 Retards Cell Cycle Entry through p27Kip1, pRB Relative p130, and Altered E2F Regulation , 2000, Molecular and Cellular Biology.

[9]  M. Eilers,et al.  Cyclin E‐mediated elimination of p27 requires its interaction with the nuclear pore‐associated protein mNPAP60 , 2000, The EMBO journal.

[10]  R. Medema,et al.  AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 , 2000, Nature.

[11]  R. Pardi,et al.  Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity , 2000, Nature.

[12]  I. Weinstein,et al.  Multiple functions of p27Kip1 and its alterations in tumor cells: a review , 2000, Journal of cellular physiology.

[13]  N. Copeland,et al.  Characterization of the mouse JAB1 cDNA and protein. , 2000, Gene.

[14]  M. Korbonits,et al.  Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. , 1999, The Journal of clinical endocrinology and metabolism.

[15]  J. Wass,et al.  Are Markers of Proliferation Valuable in the Histological Assessment of Pituitary Tumours? , 1999, Pituitary.

[16]  Andrea C. Carrano,et al.  Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. , 1999, Genes & development.

[17]  M. Scheffner.  Moving protein heads for breakdown , 1999, Nature.

[18]  J. Kato,et al.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 , 1999, Nature.

[19]  D. Lüdecke,et al.  Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. , 1999, European journal of endocrinology.

[20]  A. Koff,et al.  Cell-Free Degradation of p27kip1, a G1 Cyclin-Dependent Kinase Inhibitor, Is Dependent on CDK2 Activity and the Proteasome , 1999, Molecular and Cellular Biology.

[21]  G. Maira,et al.  Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. , 1999, Journal of clinical pathology.

[22]  James M. Roberts,et al.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.

[23]  L. Jin,et al.  DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. , 1998, The American journal of pathology.

[24]  M. Korbonits,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other , 2022 .

[25]  V. Godfrey,et al.  CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. , 1998, Genes & development.

[26]  S. Melmed,et al.  Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. , 1998, The Journal of endocrinology.

[27]  R. Kraft,et al.  A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  R. Aguiar,et al.  Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours , 1998, Oncogene.

[29]  T. Sano,et al.  Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  Bruno Amati,et al.  Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1 , 1997, The EMBO journal.

[31]  B. Scheithauer,et al.  Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. , 1997, The American journal of pathology.

[32]  K. Mimori,et al.  p27 expression and gastric carcinoma , 1997, Nature Medicine.

[33]  S. Shousha,et al.  High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  James M. Roberts,et al.  Cyclin E-CDK2 is a regulator of p27Kip1. , 1997, Genes & development.

[35]  R. Fahlbusch,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression of Glucocorticoid Receptor Gene Isoforms in Corticotropin-Secreting Tumors* , 2022 .

[36]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[37]  L. Jin,et al.  Aberrant p27kip1 expression in endocrine and other tumors. , 1997, The American journal of pathology.

[38]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[39]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[40]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[41]  T. Toda,et al.  A new group of conserved coactivators that increase the specificity of AP-1 transcription factors , 1996, Nature.

[42]  L. Jin,et al.  Transforming growth factor-beta and p27 expression in pituitary cells. , 1996, Endocrinology.

[43]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[44]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[45]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[46]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[47]  J. Massagué,et al.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. , 1995, Cancer research.

[48]  A. Norton,et al.  Brief, high‐temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues , 1994, The Journal of pathology.

[49]  G. Makara,et al.  Corticotroph, somatotroph and mammotroph cell kinetics in the postnatal infant female rat , 1993, Histochemistry.

[50]  T. Yoshimoto,et al.  Molecular analysis of p21 and p27 genes in human pituitary adenomas. , 1997, British Journal of Cancer.

[51]  R. Fahlbusch,et al.  Proliferation parameters for pituitary adenomas. , 1996, Acta neurochirurgica. Supplement.

[52]  B. Scheithauer,et al.  Assessment of mitotic activity in pituitary adenomas and carcinomas , 1996, Endocrine pathology.